In addition, other small randomized studies have shown that statins can improve certain surrogate endpoints in HF (e.g. LVEF, BNP, inflammatory markers), but not major outcomes (e.g. mortality, cardiovascular hospitalization), although it appears that most of the studies might not be adequately powered to assess major clinical outcomes12,30,70–77. This evidence concerns the gene NPPB and hydrops fetalis.